2016 - IPITA - Stem Cell Derived Beta Cells Workshop

This page contains exclusive content for the member of the following sections: TTS, IPITA. Log in to view.

Clinical Targets

15.1 - Allogeneic and autologous mode of pluripotent stem cells transplantation in beta cell replacement: Which way to go?

Presenter: Lorenzo, Piemonti, Milan, Italy
Authors: Lorenzo Piemonti

In designing cell-based treatments starting with pluripotent stem cell, a key decision is whether to use an autologous-, an allogeneic-, or a hybrid-matched approach. This choice has important implications for the manufacturing process and the associated infrastructure and could affect the design of the preclinical studies. The lack of an effective method of inducing immune tolerance to maintain graft survival is a major roadblock for cell-based therapies and poor stem cell survival and engraftment after delivery is partly due to immune response triggered by the host’s immune reaction. A great advantage of natural patient-derived (autologous) cell is that there will be no host versus graft immunological reaction, but this advantage could be limited by the autoimmune response in the context of type 1 diabetes. From the presentation it will possible to recognize a number of issues that could be decisive in influencing  the balance of advantage between allogeneic and autologous cells

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6